Shortâ term and longâ term impacts of Helicobacter pylori eradication with reverse hybrid therapy on the gut microbiota
dc.contributor.author | Hsu, Ping‐i | |
dc.contributor.author | Pan, Chao‐yu | |
dc.contributor.author | Kao, John Y | |
dc.contributor.author | Tsay, Feng‐woei | |
dc.contributor.author | Peng, Nan‐jing | |
dc.contributor.author | Kao, Sung‐shuo | |
dc.contributor.author | Chen, Yan‐hua | |
dc.contributor.author | Tsai, Tzung‐jiun | |
dc.contributor.author | Wu, Deng‐chyang | |
dc.contributor.author | Tsai, Kuo‐wang | |
dc.date.accessioned | 2020-01-13T15:04:37Z | |
dc.date.available | WITHHELD_11_MONTHS | |
dc.date.available | 2020-01-13T15:04:37Z | |
dc.date.issued | 2019-11 | |
dc.identifier.citation | Hsu, Ping‐i ; Pan, Chao‐yu ; Kao, John Y; Tsay, Feng‐woei ; Peng, Nan‐jing ; Kao, Sung‐shuo ; Chen, Yan‐hua ; Tsai, Tzung‐jiun ; Wu, Deng‐chyang ; Tsai, Kuo‐wang (2019). "Shortâ term and longâ term impacts of Helicobacter pylori eradication with reverse hybrid therapy on the gut microbiota." Journal of Gastroenterology and Hepatology 34(11): 1968-1976. | |
dc.identifier.issn | 0815-9319 | |
dc.identifier.issn | 1440-1746 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/152555 | |
dc.description.abstract | Background and AimsAntiâ Helicobacter pylori therapy may lead to the growth of pathogenic or antibioticâ resistant bacteria in the gut. The study aimed to investigate the shortâ term and longâ term impacts of H. pylori eradication with reverse hybrid therapy on the components and macrolide resistance of the gut microbiota.MethodsHelicobacter pyloriâ related gastritis patients were administered a 14â day reverse hybrid therapy. Fecal samples were collected before treatment and at the end of week 2, week 8, and week 48. The V3â V4 region of the bacterial 16S rRNA gene in fecal specimens was amplified by polymerase chain reaction and sequenced on Illumina MiSeq platform. Additionally, amplification of erm(B) gene (encoding erythromycin resistance methylase) was performed.ResultsReverse hybrid therapy resulted in decreased relative abundances of Firmicutes (from 62.0% to 30.7%; P < 0.001) and Actinobacteria (from 3.4% to 0.6%; 0.032) at the end of therapy. In contrast, the relative abundance of Proteobacteria increased from 10.2% to 49.1% (0.002). These microbiota alterations did not persist but returned to the initial levels at week 8 and week 48. The amount of erm(B) gene in fecal specimens was comparable with the pretreatment level at week 2 but increased at week 8 (0.025) and then returned to the pretreatment level by week 48.ConclusionsHelicobacter pylori eradication with reverse hybrid therapy can lead to shortâ term gut dysbiosis. The amount of erm(B) gene in the stool increased transiently after treatment and returned to the pretreatment level at 1â year postâ treatment. | |
dc.publisher | Wiley Periodicals, Inc. | |
dc.subject.other | erm(B) | |
dc.subject.other | treatment | |
dc.subject.other | dysbiosis | |
dc.subject.other | microbiome | |
dc.subject.other | Helicobacter pylori | |
dc.title | Shortâ term and longâ term impacts of Helicobacter pylori eradication with reverse hybrid therapy on the gut microbiota | |
dc.type | Article | |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | https://deepblue.lib.umich.edu/bitstream/2027.42/152555/1/jgh14736_am.pdf | |
dc.description.bitstreamurl | https://deepblue.lib.umich.edu/bitstream/2027.42/152555/2/jgh14736.pdf | |
dc.identifier.doi | 10.1111/jgh.14736 | |
dc.identifier.source | Journal of Gastroenterology and Hepatology | |
dc.identifier.citedreference | Caporaso JG, Bittinger K, Bushman FD et al. PyNAST: a flexible tool for aligning sequences to a template alignment. Bioinformatics 2010; 26: 266 â 267. | |
dc.identifier.citedreference | Imhann F, Bonder MJ, Vich Vila A et al. Proton pump inhibitors affect the gut microbiome. Gut 2016; 65: 740 â 748. | |
dc.identifier.citedreference | Portillo A, Ruizâ Larrea F, Zarazaga M, Alonso A, Martinez JL, Torres C. Macrolide resistance genes in Enterococcus spp. Antimicrob. Agents Chemother. 2000; 44: 967 â 971. | |
dc.identifier.citedreference | Jakobsson HE, Jernberg1 C, Andersson AF et al. Shortâ term antibiotic treatment has differing longâ term impacts on the human throat and gut microbiome. PLoS ONE 2010; 5: e9836. https://doi.org/10.1371/journal.pone.0009836. | |
dc.identifier.citedreference | Oh B, Kim BS, Kim JW et al. The effect of probiotics on gut microbiota during the Helicobacter pylori eradication: a randomized controlled trial. Helicobacter 2016; 21: 165 â 174. | |
dc.identifier.citedreference | Hsu PI, Pan CY, Kao JY et al. Helicobacter pylori eradication with bismuth quadruple therapy leads to dysbiosis of gut microbiota with an increased relative abundance of Proteobacteria and decreased relative abundances of Bacteroidetes and Actinobacteria. Helicobacter 2018; 23: e12498. https://doi.org/10.1111/hel.12498. | |
dc.identifier.citedreference | Sheu BS, Wu MS, Chiu CT et al. Consensus on the clinical management, screeningâ toâ treat, and surveillance of Helicobacter pylori infection to improve gastric cancer control on a nationwide scale. Helicobacter 2017; 22. https://doi.org/10.1111/hel.12368. | |
dc.identifier.citedreference | Mahachai V, Vilaichone RK, Pittayanon R et al. Helicobacter pylori management in ASEAN: the Bangkok consensus report. J. Gastroenterol. Hepatol. 2018; 33: 37 â 56. | |
dc.identifier.citedreference | Chey WD, Leontiadis GI, Howden CW et al. ACG clinical guideline: treatment of Helicobacter pylori infection. Am. J. Gastroenterol. 2017; 112: 212 â 239. | |
dc.identifier.citedreference | Hsu PI, Lin PC, Graham DY. Hybrid therapy for Helicobacter pylori infection: a systemic review and metaâ analysis. World J. Gastroenterol. 2015; 21: 12954 â 12962. | |
dc.identifier.citedreference | Hsu PI, Kao SS, Wu DC et al. A randomized controlled study comparing reverse hybrid therapy and standard triple therapy for Helicobacter pylori infection. Medicine (Baltimore) 2015; 94: e2104. | |
dc.identifier.citedreference | Hsu PI, Tsay FW, Graham DY et al. Equivalent efficacies of reverse hybrid and bismuth quadruple therapies in eradication of Helicobacter pylori infection in a randomized controlled trial. Clin. Gastroenterol. Hepatol. 2018; 16: 1427 â 1433. | |
dc.identifier.citedreference | Yap TW, Gan HM, Lee YP et al. Helicobacter pylori eradication causes perturbation of human gut microbiome in young adults. PLoS ONE 2016; 11: e0151893. | |
dc.identifier.citedreference | Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 2014; 30: 2114 â 2120. | |
dc.identifier.citedreference | Zhang J, Kobert K, Flouri T, Stamatakis A. PEAR: a fast and accurate Illumina Pairedâ End reAd mergeR. Bioinformatics 2014; 30: 614 â 620. | |
dc.identifier.citedreference | Caporaso JG, Kuczynski J, Stombaugh J et al. QIIME allows analysis of highâ throughput community sequencing data. Nat. Methods 2010; 75: 335 â 336. | |
dc.identifier.citedreference | Edgar RC. Search and clustering orders of magnitude faster than BLAST. Bioinformatics 2010; 26: 2460 â 2461. | |
dc.identifier.citedreference | Lozupone C, Knight R. UniFrac: a new phylogenetic method for comparing microbial communities. Appl. Environ. Microbiol. 2005; 71: 8228 â 8235. | |
dc.identifier.citedreference | Vazquezâ Baeza Y, Pirrung M, Gonzalez A et al. EMPeror: a tool for visualizing highâ throughput microbial community data. Gigascience 2013; 2: 16. https://doi.org/10.1186/2047â 217Xâ 2â 16. | |
dc.identifier.citedreference | Khan I, Azhar EI, Abbas AT. Metagenomic analysis of antibioticâ induced changes in gut microbiota in a pregnant rat model. Front. Pharmacol. 2016; 7: 104. https://doi.org/10.3389/fphar.2016.00104. | |
dc.identifier.citedreference | Murata M, Sugimoto M, Otsuka T et al. Successful Helicobacter pylori eradication therapy improves symptoms of chronic constipation. Helicobacter 2018; 23: e12543. | |
dc.identifier.citedreference | Imase K, Takahashi M, Tanaka A et al. Efficacy of Clostridium butyricum preparation concomitantly with Helicobacter pylori eradication therapy in relation to changes in the intestinal microbiota. Microbiol. Immunol. 2008; 52: 156 â 161. | |
dc.identifier.citedreference | Chen L, Xu W, Lee A et al. The impact of Helicobacter pylori infection, eradication therapy and probiotic supplementation on gut microenvironment homeostasis: an openâ label, randomized clinical trial. EBioMedicine 2018; 35: 87 â 96. | |
dc.identifier.citedreference | Arnold IC, Müller A. Helicobacter pylori: does gastritis prevent colitis? Inflamm Intest Dis 2016; 1: 102 â 112. | |
dc.identifier.citedreference | Luther J, Dave M, Higgins PD et al. Association between Helicobacter pylori infection and inflammatory bowel disease: a metaâ analysis and systematic review of the literature. Inflamm. Bowel Dis. 2010; 16: 1077 â 1084. | |
dc.identifier.citedreference | Dunn BE, Cohen H, Blaser MJ. Helicobacter pylori. Clin. Microbiol. Rev. 1997; 10: 720 â 741. | |
dc.identifier.citedreference | Sjolund M, Wreiber K, Andersson DI. Long term persistence of resistant Enterococcus species after antibiotics to eradicate Helicobacter pylori. Ann. Intern. Med. 2003; 139: 483 â 487. | |
dc.identifier.citedreference | Taitâ Kamradt A, Davies T, Appelbaum PC et al. Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America. Antimicrob. Agents Chemother. 2000; 44: 3395 â 3401. | |
dc.identifier.citedreference | Wierzbowski AK, Nichol K, Laing N et al. Macrolide resistance mechanisms among Streptococcus pneumoniae isolated over 6 years of Canadian Respiratory Organism Susceptibility Study (CROSS) (1998â 2004). J. Antimicrob. Chemother. 2007; 60: 733 â 740. | |
dc.identifier.citedreference | Fujimura KE, Slusher NA, Cabana MD et al. Role of gut microbiota in defining human health. Expert Rev Anti Infect 2014; 8: 435 â 454. | |
dc.identifier.citedreference | Shreiner AB, Kao JY, Young VB. The gut microbiome in health and in disease. Curr. Opin. Gastroenterol. 2015; 31: 69 â 75. | |
dc.identifier.citedreference | Cani PD, Bibiloni R, Knauf C et al. Changes in gut microbiota control metabolic endotoxemiaâ induced inflammation in highâ fat dietâ induced obesity and diabetes in mice. Diabetes 2008; 57: 1470 â 1481. | |
dc.identifier.citedreference | Tremaroli V, Backhed F. Functional interactions between the gut microbiota and host metabolism. Nature 2012; 489: 242 â 249. | |
dc.identifier.citedreference | Vakil N, Megraud E. Eradication treatment for Helicobacter pylori. Gastroenterology 2007; 133: 985 â 1001. | |
dc.identifier.citedreference | Suerbaum S, Michetti P. Helicobacter pylori infection. N. Engl. J. Med. 2002; 347: 1175 â 1186. | |
dc.identifier.citedreference | Sung JJY, Chung SCS, Ling TKW et al. Antibacterial treatment of gastric ulcer associated with Helicobacter pylori. N. Engl. J. Med. 1995; 332: 139 â 142. | |
dc.identifier.citedreference | Doorakkers E, Lagergren J, Engstrand L, Brusselaers N. Eradication of Helicobacter pylori and gastric cancer: a systematic review and metaâ analysis of cohort studies. J. Natl. Cancer Inst. 2016; 108:pii: djw132. https://doi.org/10.1093/jnci/djw132. | |
dc.identifier.citedreference | Graham DY, Akiko S. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat. Clin. Pract. Gastroenterol. Hepatol. 2008; 5: 321 â 331. | |
dc.identifier.citedreference | Huang CC, Tsai KW, Tsai TJ et al. Update on the firstâ line treatment for Helicobacter pylori infectionâ a continuing challenge from an old enemy. Biomark Res. 2017; 5: 23. https://doi.org/10.1186/s40364â 017â 0103â x. | |
dc.identifier.citedreference | Hsu PI, Wu DC, Wu JY et al. Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter 2011; 16: 139 â 145. | |
dc.identifier.citedreference | Trifan A, Girleanu I, Cojocariu C et al. Pseudomembranous colitis associated with a triple therapy for Helicobacter pylori eradication. World J. Gastroenterol. 2013; 19: 7476 â 7479. | |
dc.identifier.citedreference | Bühling A, Radun D, Müller WA et al. Influence of antiâ Helicobacter tripleâ therapy with metronidazole, omeprazole, and clarithromycin on intestinal microflora. Aliment. Pharmacol. Ther. 2001; 15: 1445 â 1452. | |
dc.identifier.citedreference | Jackson MA, Goodrich JK, Maxan ME et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut 2016; 65: 749 â 756. | |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.